Conditional EU approval of Pixuvri becomes standard authorisation

The European Commission (EC) has converted conditional approval of Pixuvri into a standard marketing authorisation in patients with aggressive non-Hodgkin B-cell lymphoma, French pharma Servier has announced.

The approval is based on data from the global clinical development of Pixuvri (pixantrone).

“There are limited treatment options for multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma,” said Prof Pier Luigi Zinzani from the University of Bologna Institute of Haematology and Medical Oncology in Bologna, Italy.

“Pixuvri has demonstrated efficacy in late stage disease and the EC approval confirms Pixuvri as a treatment option for these patients.”

The pivotal Phase III study, PIX301 compared Pixuvri monotherapy with physician’s choice of treatment in 140 patients with relapsed or refractory aggressive non-Hodgkin lymphoma, 50% of whom had been previously treated with rituximab.

Pixuvri was shown to be beneficial in these patients: 20% of patients responded completely to Pixuvri compared with 5.7% of patients receiving other agents.

To satisfy requirements of the conditional authorization, a further Phase III clinical study, PIX306, was completed to provide additional efficacy data to confirm the benefit of Pixuvri in patients that had received prior treatment regimens containing rituximab.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...

First generic remdesivir for COVID-19 treatment launched

Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19. Remdesivir is an antiviral...

Vividion Therapeutics partners with Roche on novel E3 ligases

San Diego biotech, Vividion Therapeutics, is collaborating with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3...

Related news

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...